Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET

Company Participants

Carlo Tanzi - Investor Relations
Eric Shaff - Chief Executive Officer
Lisa von Moltke - Chief Medical Officer
Teresa Young - EVP, Chief Commercial & Strategy Officer,
Marella Thorell - Chief Financial Officer
Matthew Henn - EVP, Chief Scientific Officer

Conference Call Participants

Joseph Thome - TD Cowen
Caroline Pocher - JPMorgan
Edward Tenthoff - Piper Sandler

Operator

Thank you for standing by. My name is Bella, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2024 Seres Therapeutics Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers remarks there will be a question-and-answer session. [Operator Instructions] Thank you.

I would now like to turn the call over to Dr. Carlo Tanzi, Investor Relations. Please go ahead.

Carlo Tanzi

Thank you, and good morning. Our press release with the company's third quarter 2024 financial results and business updates became available at 7:00 a.m. Eastern Time this morning and can be found on the Investors & News section of the company's website. The company has also posted an updated corporate presentation to the website.

I'd like to remind you that we'll be making forward-looking statements including statements about the financial terms and future payments related to the VOWST sale, the timing and results of our clinical studies and data readouts, future product candidates, development plans and commercial opportunities, interactions with regulatory agencies, operating plans and our cash runway, our ability to generate additional capital, our planned strategic focus and anticipated timing of any of the foregoing and other statements, which are not historical facts. Actual results may differ materially.

On today's call with prepared remarks, I'm joined by Eric Shaff, Seres' President and CEO; and Marella Thorell, CFO; Dr. Lisa von Moltke, Chief Medical Officer; and Dr. Terri Young, Chief Commercial and Strategy Officer. Additional members of the team will also be available during the Q&A portion of the call.

With that, I'll pass the call to Eric.

Eric Shaff

Thank you, Carlo. And good morning, everyone. The last period has been a particularly eventful time for Seres highlighted by two major milestones. The first being our positive SER-155 Phase Ib Cohort 2 clinical results. And the second being the sale of VOWST, which has strengthened our balance sheet and provided resources to support advancement of SER-155, our lead clinical candidates.